Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Tinzaparin for the treatment of foetal growth retardation: An open-labelled randomized clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Role of spleen and liver for enhanced hemostatic competence following administration of adrenaline to humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Venous thromboembolism in epithelial ovarian cancer. A prospective cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Prevalence and significance of anti-phosphatidylserine antibodies: A pooled analysis in 5992 patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Neurodevelopmental disorder in children believed to have isolated mild ventriculomegaly prenatally

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A new intelligent stocking for quantification of edema in the lower limbs

    Research output: Contribution to conferenceConference abstract for conferenceResearchpeer-review

  3. Danish Sonographers’ Experiences of the Introduction of "Moderate Risk" in Prenatal Screening for Down Syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: Foetal growth retardation (FGR) is a leading cause of perinatal death and long-term harms at survivors. Placental infarction plays a role in FGR, yet, no trials have evaluated whether low molecular weight heparins increase birth weight in ongoing FGR pregnancies.

METHODS: An open-labelled randomized trial in Denmark during 2011-2016, including singleton pregnant women with FGR (estimated foetal weight < 2.3 percentile) diagnosed before gestational weeks 32. Participants were randomly assigned using sealed, blinded envelopes 1:1 to tinzaparin (4500 IU daily until 37 gestational weeks) or no tinzaparin. The primary outcomes were the observed birthweight relative to the expected for gestational age and gender, and foetal growth rates in the two trial groups evaluated by an intention to treat analysis.

RESULTS: We enrolled 53 women. The mean gestational age was 261 days in the tinzaparin group and 246 days in the no treatment group. The mean birth weight was 2229 g in the tinzaparin group compared to 1968 g in the no treatment group. However, the birth weight relative to the expected from gestational age and gender was only 2.5 percentage points higher in the tinzaparin group [-5.1 to 10.0] (p = 0.51). The foetal growth rate during follow-up was 124 g/week in the tinzaparin group and 119 g/week in the no treatment group, a difference of 5 g/week [-19 to 29] (p = 0.67). Two perinatal deaths both occurred in the no treatment group.

CONCLUSION: We found no evidence of a tinzaparin effect on the foetal growth rate or the birth weight after adjustment for gestational age.

Original languageEnglish
JournalThrombosis Research
Volume170
Pages (from-to)38-44
Number of pages7
ISSN0049-3848
DOIs
Publication statusPublished - Oct 2018
Externally publishedYes

ID: 57105653